LIQUIDIA CORPORATION Research and Development Expense
LIQUIDIA CORPORATION (LQDA) reported Research and Development Expense of $17.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-12
- LIQUIDIA CORPORATION research and development expense for the quarter ending 2026-06-30 was $17.18M, a 185.40% increase year-over-year.
- LIQUIDIA CORPORATION research and development expense for the quarter ending 2026-03-31 was $12.57M, a 80.46% increase year-over-year.
- LIQUIDIA CORPORATION research and development expense for the quarter ending 2025-12-31 was $16.94M, a 2.84% increase year-over-year.
- LIQUIDIA CORPORATION research and development expense for the quarter ending 2025-09-30 was $9.35M, a 21.40% decline year-over-year.
- LIQUIDIA CORPORATION research and development expense for fiscal 2025 was $39.28M, a 17.90% decline from fiscal 2024.
- LIQUIDIA CORPORATION research and development expense for fiscal 2024 was $47.84M, a 10.64% increase from fiscal 2023.
- LIQUIDIA CORPORATION research and development expense for fiscal 2023 was $43.24M, a 122.50% increase from fiscal 2022.
- LIQUIDIA CORPORATION research and development expense for fiscal 2022 was $19.43M, a 5.27% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.18M 10-Q · filed 2026-08-12 | $29.75M 10-Q · filed 2026-08-12 | $46.70M derived: sum of 3 quarters · filed 2026-08-12 | $56.04M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $12.57M 10-Q · filed 2026-05-11 | $29.51M derived: sum of 2 quarters · filed 2026-05-11 | $38.86M derived: sum of 3 quarters · filed 2026-05-11 | $44.88M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $16.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $26.29M derived: sum of 2 quarters · filed 2026-03-05 | $32.31M derived: sum of 3 quarters · filed 2026-08-12 | $39.28M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $9.35M 10-Q · filed 2025-11-03 | $15.37M derived: sum of 2 quarters · filed 2026-08-12 | $22.33M 10-Q · filed 2025-11-03 | $38.81M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $6.02M 10-Q · filed 2026-08-12 | $12.99M 10-Q · filed 2026-08-12 | $29.46M derived: sum of 3 quarters · filed 2026-08-12 | $41.35M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $6.97M 10-Q · filed 2026-05-11 | $23.44M derived: sum of 2 quarters · filed 2026-05-11 | $35.33M derived: sum of 3 quarters · filed 2026-05-11 | $44.75M derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | $16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $28.36M derived: sum of 2 quarters · filed 2026-03-05 | $37.78M derived: sum of 3 quarters · filed 2026-03-05 | $47.84M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $11.89M 10-Q · filed 2025-11-03 | $21.31M derived: sum of 2 quarters · filed 2025-11-03 | $31.37M 10-Q · filed 2025-11-03 | $44.20M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | $9.42M 10-Q · filed 2025-08-12 | $19.48M 10-Q · filed 2025-08-12 | $32.31M derived: sum of 3 quarters · filed 2026-03-05 | $39.75M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $10.06M 10-Q · filed 2025-05-08 | $22.89M derived: sum of 2 quarters · filed 2026-03-05 | $30.33M derived: sum of 3 quarters · filed 2026-03-05 | $48.02M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $12.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $20.27M derived: sum of 2 quarters · filed 2026-03-05 | $37.96M derived: sum of 3 quarters · filed 2026-03-05 | $43.24M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $7.44M 10-Q · filed 2024-11-13 | $25.14M derived: sum of 2 quarters · filed 2024-11-13 | $30.41M 10-Q · filed 2024-11-13 | $35.39M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $17.70M 10-Q · filed 2024-08-07 | $22.97M 10-Q · filed 2024-08-07 | $27.95M derived: sum of 3 quarters · filed 2024-08-07 | $32.46M derived: sum of 4 quarters · filed 2024-08-07 | ||||
| 2023-03-31 | $5.28M 10-Q · filed 2024-05-13 | $10.25M derived: sum of 2 quarters · filed 2024-05-13 | $14.77M derived: sum of 3 quarters · filed 2024-05-13 | $19.98M derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $4.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $9.49M derived: sum of 2 quarters · filed 2024-03-13 | $14.71M derived: sum of 3 quarters · filed 2024-03-13 | $19.43M 10-K · filed 2024-03-13 | ||||
| 2022-09-30 | $4.51M 10-Q · filed 2023-11-07 | $9.73M derived: sum of 2 quarters · filed 2023-11-07 | $14.46M 10-Q · filed 2023-11-07 | $19.84M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $5.22M 10-Q · filed 2023-08-10 | $9.95M 10-Q · filed 2023-08-10 | $15.33M derived: sum of 3 quarters · filed 2023-08-10 | $19.82M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $4.73M 10-Q · filed 2023-05-08 | $10.11M derived: sum of 2 quarters · filed 2023-05-08 | $14.60M derived: sum of 3 quarters · filed 2023-05-08 | $19.19M derived: sum of 4 quarters · filed 2023-05-08 | ||||
| 2021-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $9.87M derived: sum of 2 quarters · filed 2023-03-20 | $14.46M derived: sum of 3 quarters · filed 2023-03-20 | $20.52M 10-K · filed 2023-03-20 | $20.52M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $4.49M 10-Q · filed 2022-11-08 | $4.49M 10-Q · filed 2021-11-03 | $9.08M derived: sum of 2 quarters · filed 2022-11-08 | $15.14M 10-Q · filed 2022-11-08 | $15.14M 10-Q · filed 2021-11-03 | $20.38M derived: sum of 4 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $4.59M 10-Q · filed 2022-08-11 | $4.60M 10-Q · filed 2021-08-10 | $10.65M 10-Q · filed 2022-08-11 | $10.65M 10-Q · filed 2021-08-10 | $15.90M derived: sum of 3 quarters · filed 2022-08-11 | $23.56M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $6.05M 10-Q · filed 2022-05-12 | $6.05M 10-Q · filed 2021-05-13 | $11.30M derived: sum of 2 quarters · filed 2022-05-12 | $18.96M derived: sum of 3 quarters · filed 2022-05-12 | $27.45M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $12.91M derived: sum of 2 quarters · filed 2022-03-17 | $21.40M derived: sum of 3 quarters · filed 2022-03-17 | $32.22M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $7.66M 10-Q · filed 2021-11-03 | $16.15M derived: sum of 2 quarters · filed 2021-11-03 | $26.97M 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | $8.49M 10-Q · filed 2021-08-10 | $19.31M 10-Q · filed 2021-08-10 | ||||||
| 2020-03-31 | $10.82M 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | $40.49M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |